Table 1.
Baseline characteristics of patients treated with tacrolimus
| Patient | Age/Sex | Race | CTD | Serum auto-antibody | HRCT pattern | Pathologic diagnosis | Length of tacrolimus therapy (months) | Concurrent therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | 47/F | AA | UCTD | ANA, dsDNA, anti-RNP | fNSIP/OP | OP | 27 | azathioprine 150mg daily |
| 2 | 47/M | C | UCTD | ANA, anti-Ro | fNSIP | None | 25 | azathioprine 150mg daily |
| 3 | 66/M | C | DM | none | OP/fNSIP | OP/fNSIP | 64 | MMF 1500mg BID |
| 4 | 63/M | C | DM | ANA, anti-MI-2 | UIP | fNSIP/UIP | 6 | MMF 500mg BID |
| 5 | 49/F | AA | PM | ANA | OP/fNSIP | OP/NSIP | 53 | azathioprine 50mg |
| 6 | 60/F | C | ASA | Anti-Jo-1 | fNSIP | None | 12 | MMF 500mg BID |
| 7 | 50/F | C | ASA | ANA, anti-Ro, Jo-1 | DAD | None | 26 | IV cyclophosphamide 500mg weekly |
| 8 | 71/M | C | ASA | ANA, dsDNA, anti-Ro, RF, anti-Jo-1 | fNSIP/DAD | OP/DAD | 17 | Azathioprine 150mg |
| 9 | 50/M | C | ASA | ANA, dsDNA, anti-Ro, RF, anti-Jo-1 | NSIP | cNSIP with interstitial fibrosis | 34 | PO cyclophosphamide 150mg daily |
| 10 | 41/F | AA | ASA | dsDNA, anti-Ro, anti-Jo-1 | fNSIP | None | 110 | azathioprine 150mg daily |
| 11 | 57/F | AA | ASA | ANA, anti-Ro, anti-Jo-1 | fNSIP | UIP | 78 | azathioprine 50mg daily |
| 12 | 73/F | C | ASA | Anti-Ro, anti-Jo-1 | fNSIP | None | 14 | azathioprine 150mg daily |
| 13* | 66/F | C | UCTD | ANA | fNSIP | UIP | 1 | azathioprine 150mg daily |
| 14* | 78/F | C | UCTD | ANA, anti-Ro | fNSIP | UIP | 1 | MMF 500mg BID |
| 15* | 53/M | AA | UCTD | ANA, anti-RNP, RF, anti-CCP | UIP | none | unknown | azathioprine 50mg daily |
| 16* | 63/F | AA | ASA | Anti-Jo-1 | fNSIP/cNSIP | UIP/OP | unknown | azathioprine 50mg daily |
| 17* | 63/M | C | DM | SSA | NSIP | OP | 10 | azathioprine 100mg daily |
AA: African American; ANA: anti-nuclear antibody; ASA: anti-synthetase syndrome; BID: twice a day; C: Caucasian; cNSIP: cellular non-specific interstitial pneumonia; CTD: connective tissue disease; DAD: diffuse alveolar damage; DM: dermatomyositis; F: female; fNSIP: fibrosing non-specific interstitial pneumonia; HRCT: high-resolution computed tomography; IV: intravenous; M: male; MMF: mycophenolate mofetil; OP: organizing pneumonia; PM: polymyositis; PO: by mouth; RF: rheumatoid factor; RNP: ribonuclear protein; UCTD: undifferentiated connective tissue disease; UIP: usual interstitial pneumonia.
*
excluded from efficacy analysis due to significant missing data